Breast Biopsy Devices Companies

The global breast biopsy market is projected to reach USD 3,261.7 million by 2030 from USD 2,384.1 million in 2025 at a CAGR of 6.5% from 2025 to 2030. The market is growing due to the increasing incidence of breast cancer worldwide, the rise in breast cancer screening programs focused on early detection, and the growing demand for minimally invasive and non-invasive diagnostic procedures that provide greater patient comfort and faster recovery times.

Breast cancer is becoming increasingly common worldwide, highlighting the importance of early diagnosis. Modern imaging techniques, such as 3D mammography and ultrasound, have revolutionized the field. There is also a growing preference for minimally invasive surgical approaches, leading to a rising demand for needle biopsy and vacuum-assisted biopsy devices. Screening programs, particularly in developed countries, are driving market growth. Additionally, the expansion of healthcare spending, the development of diagnostic infrastructure in emerging markets, and innovations in biopsy techniques and device accuracy contribute to this market expansion.

To know about the assumptions considered for the study download the pdf brochure

Key players in the breast biopsy devices market include Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), QIAGEN (Germany), and Biocept, Inc. (US).

Hologic Inc. is a leading company in the breast biopsy devices market. It is dedicated to women's health and equipped with a wide range of advanced technologies. Its innovative products, such as the Brevera Breast Biopsy System with CorLumina Imaging Technology, utilize real-time imaging along with vacuum-assisted tissue acquisition to enhance diagnostic accuracy and improve the efficiency of biopsy procedures. The company continues to strengthen its position in the market through strategic acquisitions, including SOMATEX Medical Technologies GmbH and Endomag, which expand its capabilities in biopsy site markers and localization technologies. With a strong global presence, substantial resources, a focus on research and development, and a steadfast commitment to innovation, Hologic is well-positioned to remain a leader in breast biopsy solutions.

Becton, Dickinson and Company (BD) is a leading player in the breast biopsy devices market, offering innovative solutions such as the EnCor Enspire and BD EleVation systems. EnCor Enspire is an advanced, vacuum-assisted breast biopsy system that features an intuitive touchscreen display and real-time visualization of needle activity. It also offers in-breast adaptability, allowing clinicians to adjust tissue density and lesion size without having to reinsert the probe. Its ergonomic design includes a palm-sized handpiece and integrated headlights, enhancing maneuverability across MRI, ultrasound, and stereotactic modalities. Additionally, features like a top-load canister and snap-in tubing cassette simplify setup and inventory management. Complementing this, the BD EleVation system is an ergonomic, handheld, vacuum-assisted instrument designed for ultrasound-guided procedures.

Devicor Medical Products, Inc., a subsidiary of Leica Biosystems and part of Danaher Corporation, is a leading company in the breast biopsy devices market, particularly known for its Mammotome vacuum-assisted biopsy systems. Founded in 2010 after being carved out from Johnson & Johnson, Devicor has expanded its portfolio through strategic acquisitions, including the HydroMARK breast biopsy marker, which enhances its offerings in tissue marking solutions. The company's commitment to minimally invasive procedures and diagnostic excellence has established its reputation among healthcare professionals, with products available in over 50 countries worldwide. Devicor's acquisition by Leica Biosystems has further strengthened its position by combining anatomical pathology solutions with advanced biopsy technologies, facilitating precise breast cancer diagnosis and treatment.

Market Ranking:

The breast biopsy market is somewhat concentrated and primarily dominated by three main competitors: Hologic, Inc. (US), Devicor Medical Products, Inc. (a subsidiary of Danaher Corporation) (US), and Becton, Dickinson, and Company (BD) (US). Hologic holds a significant market share of approximately 60–65% due to its robust and technologically advanced product portfolio, which includes vacuum-assisted biopsy systems like Affirm and Eviva, prone biopsy tables, and integrated imaging-guided solutions.

Devicor Medical Products, under the Leica Biosystems brand, is another key player in the breast biopsy devices market. The company is well-known for its Mammotome brand, which offers a range of vacuum-assisted breast biopsy (VABB) systems designed for minimally invasive tissue sampling.

Becton, Dickinson and Company (BD) boasts a strong global presence in over 190 countries, supported by extensive manufacturing, research and development, and commercial operations. The remaining market share (approximately 35–40%) consists of regional and niche competitors who foster innovation and provide opportunities for start-ups.

Related Reports:

Breast Biopsy Devices Market by Product (Needle: Core, FNAB, VAB; Equipment, Wire, Guidance system, Table, Assay kit), Procedure (Needle, Liquid: CTC, CTDNA; Open), Application (Screening, Monitoring), End User (Hospital, Clinic) - Global Forecasts to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com